Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

Latest News

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

View Press Release View All

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Latest Financial Results

Q1 2025

Quarter Ended Mar 31, 2025
Earnings Release
PDF HTML
Audio
Earnings Webcast
Earnings Presentation
PDF
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080

Investor Relations

Rigel Pharmaceuticals, Inc.
ir@rigel.com

Transfer Agent

EQ Shareowner Services
T: 800-401-1957